Biotech Breakouts, Flying Taxis, and the Rise of Cashless Machines

A breakthrough epilepsy trial is sending one biotech stock into record territory, while a White House-backed program is helping bring the air taxi dream a little closer to reality. Meanwhile, one payments platform is quietly building a powerful business behind the shift toward cashless machines.

Elite Trade Club and Alumni Ventures are teaming up this month only to give readers early access to high-growth startup opportunities, including some of today’s most exciting AI First, Deep Tech, Quantum Computing, and Space companies co-invested alongside top VC firms like Andreessen Horowitz (a16z), Bessemer, & Y Combinator.

You get:

Don’t miss your chance before access closes.

Join Alumni Ventures Syndicate Today

Futures are pointing higher as traders react to signs that the Iran conflict may be nearing its end after comments from President Trump. With geopolitical nerves easing, risk appetite is creeping back into the market. Treasury yields are also ticking lower, giving stocks a bit of breathing room to start the session.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings (Premarket):

Earnings (Aftermarket)

Earnings (Time not supplied)

Economic Reports:

Xenon Pharmaceuticals [XENE] just delivered the kind of biotech update that can wake a stock up fast. Shares surged after the company reported strong Phase 3 results for its epilepsy drug azetukalner, with patients seeing meaningful reductions in seizure frequency compared with placebo. The trial met both its primary and key secondary endpoints, and the results even exceeded those of the company's earlier Phase 2 study.

The rally has pushed the stock through its previous record high, sending it into fresh territory as investors rethink the drug’s commercial potential. Xenon now plans to file for FDA approval in the third quarter of 2026, and if approved, azetukalner would become the only KV7 potassium channel opener available for epilepsy patients.

My Take For You: Biotech stocks love big clinical wins, but they also love giving some of that excitement back after the first surge. With the stock now riding new highs, waiting for a pullback could be the calmer way to approach it.

My Verdict: A major clinical milestone and a potential first-in-class therapy. The science looks strong, but after smashing through record highs, the easy momentum may already be behind us.

Joby Aviation, Inc. [JOBY] just got a big credibility boost after being selected to participate in a White House-backed program designed to bring electric air taxis into real-world operations across the United States. The initiative sent the stock soaring to record highs. It could allow Joby to begin early services across 10 states, including major markets like New York, Texas, and Florida, potentially accelerating its timeline toward commercial flights.

For a company building aircraft that still feel like science fiction to most, this is a meaningful step. The program brings regulators, local governments, and industry together to test how electric vertical takeoff and landing aircraft can actually operate in U.S. airspace. If it works, Joby could move from test flights to real passenger routes sooner than you might have thought possible.

My Take For You: The air taxi story has always been exciting but distant. Programs like this make it feel more real, but the timeline to widespread adoption is still long. Treat the stock like a long runway idea rather than a quick trade.

My Verdict: A strong validation moment for the technology, but commercialization is still a journey. Big vision, patient investors required.

I predicted the 1987 crash six weeks early. I called the fall of the Berlin Wall. I pinpointed the exact bottom in 2009.

Now I'm staking my reputation on March 26, 2026 - the day I believe Elon will announce the SpaceX IPO.

Bloomberg is calling it "the biggest listing of ALL TIME."

A $1.5 TRILLION valuation... the "wealth-building" moment of the decade.

Today, I'll show you how to get in before the big announcement.

Click Here to See How to Secure Your "SpaceX Access Code"

Nayax, Ltd. [NYAX] just conjured up another strong growth quarter as the company continues turning everyday machines into digital payment hubs. The payments platform, which powers cashless transactions for vending machines, kiosks, and self-service devices, reported solid revenue growth in its latest results, showing that the shift toward card and mobile payments in unattended retail is still gaining momentum.

Nayax provides the hardware, software, and payment infrastructure that lets operators run vending machines, EV chargers, laundromats, and other unattended businesses more efficiently. As more devices get connected and cash continues to fade, that ecosystem keeps expanding. Management also pointed to rising transaction volume and a growing installed base of devices as key drivers of the business.

My Take For You: This is one of those stories that quietly rides long-term trends like digital payments and automation. The growth story is intact, but the stock can be volatile around earnings, so patience often pays off.

My Verdict: A steady fintech-style growth play tied to the global shift toward cashless transactions. Not flashy, but the runway still looks long.

BorgWarner is edging higher in premarket trading as analysts highlight the stock as a value opportunity in the auto sector, pointing to potential upside and its expansion into AI data center infrastructure.

Coinbase is moving higher in premarket trading as the company rolls out a pioneering stablecoin insurance deal and benefits from renewed institutional interest in crypto.

Kohl’s is slipping in premarket trading as discount rivals continue pulling shoppers away, with store visits reportedly down about 5%. The pressure comes just as the retailer heads into its Q4 earnings report with expectations for a revenue decline.

Big Oil may be facing its biggest challenge yet.

A breakthrough tied to an MIT-trained scientist could unlock a fuel source that’s virtually unlimited.

According to the U.S. Department of Energy, it could last billions of years.

Once operational, the fuel itself costs nothing.

That’s why this story matters now.

Get the full details here.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.